Clinical observation of sacubitril/valsartan versus benazepril in perimenopausal hypertensive patients
- VernacularTitle:沙库巴曲缬沙坦对比贝那普利用于围绝经期高血压患者的临床观察
- Author:
Xiaoxia ZHANG
1
;
Bolin SHAO
1
;
Yingkun ZHOU
1
;
Zhanhai ZHANG
1
;
Zhiying LI
1
Author Information
1. Dept. of Cardiovascular Medicine，the First Affiliated Hospital of Nanyang Medical College，Henan Nanyang 473058，China
- Publication Type:Journal Article
- Keywords:
sacubitril/valsartan;
benazepril;
perimenopause;
hypertension;
ventricular remodeling;
inflammatory fibrosis
- From:
China Pharmacy
2026;37(4):476-479
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To compare the antihypertensive efficacy of sacubitril/valsartan versus benazepril in patients with perimenopausal hypertension， as well as their impacts on ventricular remodeling and inflammatory fibrosis. METHODS A total of 206 perimenopausal hypertensive patients in our hospital from January 1， 2023 to December 30， 2024 were retrospectively included.These patients were enrolled and divided into benazepril group （105 cases） and sacubitril/valsartan group （101 cases）. Benazepril group received Benazepril hydrochloride tablet， and sacubitril/valsartan group received Sacubitril valsartan sodium tablet. All patients were treated for 6 months. The blood pressure（systolic blood pressure and diastolic blood pressure） and blood pressure control status before and after treatment， echocardiographic indicators （left ventricular ejection fraction， left ventricular mass index， relative wall thickness， and early-diastolic peak transmitral flow velocity/early-diastolic peak velocity of the mitral annulus）， inflammatory fibrosis related indicators（high-sensitivity C-reactive protein，ratio of monocytes to lymphocytes，and ratio of neutrophils to lymphocytes）， as well as the occurrence of adverse reactions（hypotension，hyperkalemia，and angioedema） were observed in both groups before and after treatment. RESULTS The blood pressure control rate was significantly higher in the sacubitril/valsartan group than in benazepril group （ P ＜0.05）. After treatment， the blood pressure， echocardiographic indicators（except for left ventricular ejection fraction） ，and inflammatory fibrosis related indicators were significantly lower than those before treatment within the same group， and the sacubitril/valsartan group were significantly lower than the benazepril group （ P ＜0.05）. There were no statistically significant differences in the incidence of hypotension， hyperkalemia， angioedema， and overall adverse drug reactions between the two groups （ P ＞0.05）. CONCLUSIONS Compared with benazepril， sacubitril/valsartan provides superior blood-pressure control， reverses ventricular remodeling， attenuates inflammatory fibrosis in perimenopausal hypertensive patients， while maintaining a similar safety profile.
